Semaglutide ... without diabetes. Among these adults, the mean age was 67 years, the mean BMI was 32.6 kg/m 2, more than half (56%) were male, and 71% were White. Based on the model, over 3 ...

But it is an oral version of the GLP-1 analogue that holds the greatest promise for patients with diabetes - and for the company's revenues. Phase 3 trials of injectable semaglutide have shown it ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

details a statistical model analyzing the cost-effectiveness of semaglutide. It provides evidence for policymakers considering the benefits of funding semaglutide for individuals without diabetes ...

A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect ... memory function in a well ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

Oral semaglutide 14 mg was associated with better cardiometabolic outcomes than active comparators, including empaglifozin and liraglutide, among patients with T2D. Oral semaglutide improves ...

Semaglutide is a widely prescribed antidiabetic medicine that acts as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes and obesity. A 2024 study by ...

Diabetes management shouldn’t be focused narrowly on blood sugar levels, but must concurrently work at protecting cardiac and renal health too, states a recent study that found daily oral ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...